Johns Hopkins Medicine: A Cure for Sickle Cell Disease
December 13, 2023
December 13, 2023
BALTIMORE, Maryland, Dec. 13 (TNSres) -- Johns Hopkins Medicine issued the following news release:
A national, multicenter clinical trial (BMT CTN 1507) of low-dose haploidentical (half-matched) bone marrow transplant to treat severe sickle cell disease found the treatment to be safe and curative for adults with serious sickle cell-related health complications.
The findings from the phase II clinical trial will be featured Dec. 12 as a high-impact study (abstract #LBA4 . . .
A national, multicenter clinical trial (BMT CTN 1507) of low-dose haploidentical (half-matched) bone marrow transplant to treat severe sickle cell disease found the treatment to be safe and curative for adults with serious sickle cell-related health complications.
The findings from the phase II clinical trial will be featured Dec. 12 as a high-impact study (abstract #LBA4 . . .